Pharma: Page 32
-
NanoStockk via Getty Images
Q&AThat’s not Angry Birds — that’s your doctor learning about novel drugs through gaming
How pharma companies can teach physicians about mechanism of action and other medication lessons with interactive mobile games.
By Alexandra Pecci • Sept. 26, 2022 -
Stock via Getty Images
Methadone at home? Emerging tech provides new tool in the fight against opioid addiction
Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.
By Alexandra Pecci • Sept. 15, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Md Saiful Islam Khan via Getty Images
Feds could soon bring COVID-style fight to superbug threat
COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.
By Karissa Waddick • Sept. 13, 2022 -
Ground+Picture/shutterstock.com/
Sponsored by GoodRxMedication affordability’s impact on adherence and outcomes
Improved patient affordability is an important lever that can increase adherence, which in turn can improve health outcomes.
Sept. 12, 2022 -
Iryna Imago via Getty Images
Drug recalls are ticking upwards — here’s how to avoid costly pitfalls
Supply chain challenges, labor shortages and increased FDA inspections are boosting recall risks — but careful planning can keep companies in the clear.
By Kelly Bilodeau • Sept. 8, 2022 -
Artur Plawgo via Getty Images
Pharma’s renewed sickle cell investment lifts a once-shirked disease
Pfizer’s $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.
By Kelly Bilodeau • Sept. 1, 2022 -
Gabriel Kuchta via Getty Images
Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes
The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.
By Karissa Waddick • Aug. 31, 2022 -
Mario Tama via Getty Images
Parexel joins pharmacy giants in quest to boost community health clinical trials
The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.
By Taren Grom and Karissa Waddick • Aug. 30, 2022 -
Permission granted by Alvotech.
Hurdles remain in biosims market — but Alvotech is undeterred
The biosimilar developer is advancing a pipeline with high growth potential, including a copycat of Humira.
By Kelly Bilodeau • Aug. 29, 2022 -
Jikaboom via Getty Images
The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact
A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.
By Michael Gibney • Aug. 29, 2022 -
Gorodenkoff/Stock.adobe.com
Sponsored by AcoladWhy high-quality medical translations can help save lives
Crystal clear communication is becoming more important for businesses working in our increasingly connected world.
Aug. 29, 2022 -
Snezhana Kudryavtseva via Getty Images
With market success at stake, can tech help solve the diversity problem in clinical trials?
Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.
By Kelly Bilodeau • Aug. 24, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Glympse Bio’s Dr. Tram Tran
How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.
By Taren Grom • Aug. 24, 2022 -
iStock via Getty Images
Making MovesModerna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires
How the latest personnel shifts are impacting each company and the industry at large.
By Karissa Waddick • Aug. 24, 2022 -
designer491 via Getty Images
Overcoming mental health’s drug development challenges with AI
PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.
By Kelly Bilodeau • Aug. 23, 2022 -
Permission granted by Brian Goff.
Q&A // First 90 DaysFirst 90 Days: Agios Pharmaceuticals’ Brian Goff
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
By Alexandra Pecci • Aug. 22, 2022 -
cagkansayin via Getty Images
Patents, pandemics and pricing: a peek at the top drug from every big pharma
A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.
By Michael Gibney • Aug. 22, 2022 -
Drew Angerer via Getty Images
3 ways pharma can prep for Biden’s sweeping drug pricing policies
Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.
By Karissa Waddick • Aug. 18, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Takeda Oncology’s Teresa Bitetti
Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.
By Taren Grom • Aug. 17, 2022 -
Permission granted by George Magrath.
The CEO in the ophthalmologist’s coat
In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.
By Alexandra Pecci • Aug. 16, 2022 -
Evgenyi_Eg via Getty Images
Right under our noses: Could COVID-19 vaccines be better as nasal spray?
Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.
By Kelly Bilodeau • Aug. 16, 2022 -
Sarah Silbiger via Getty Images
The FDA is mulling an OTC approval for a birth control. Will politics factor in?
Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma’s OTC birth control application.
By Karissa Waddick • Aug. 15, 2022 -
Win McNamee/Staff via Getty Images
Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
By Michael Gibney • Aug. 11, 2022 -
E+ via Getty Images
As pharma M&A ramps up, U.S. execs are bullish on more deals
What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.
By Michael Gibney • Aug. 11, 2022 -
Stock via Getty Images
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022
Previous
